0O

Elekta AB (publ)LSE Elekta AB Stock Report

Last reporting period 31 Jul, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

4.229

Middle

Exchange

XLON - London Stock Exchange

0O5H.L Stock Analysis

0O

Neutral

Based on Eyestock quantitative analysis, 0O5H.L`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

51/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

39.6 %

Greatly undervalued

Market cap $B

4.229

Dividend yield

3.61 %

Shares outstanding

368.59 B

Elekta AB operates as a medical technology company. The company is headquartered in Stockholm, Stockholm and currently employs 4,614 full-time employees. The firm offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The firm has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The firm owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).

View Section: Eyestock Rating